Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Reporting from ASCO 2022 Annual Meeting in Chicago, Ian Davis comments on Prostate Cancer latest data in the metastatic setting.
He features the positive results from ENZAMET studying the addition of enzalutamide to testosterone suppression in hormone-sensitive mPC, and discusses survival data at 3 years from the TheraP trial testing 177Lu-PSMA-617 vs cabazitaxel in castration-resistant mPC progressing after docetaxel.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
